Article Text

Download PDFPDF

571 Niraparib in patients with newly diagnosed advanced ovarian brcam cancer: a post hoc analysis of the prima/engot-ov26/gog-3012 trial
  1. Jacob Korach1,
  2. Whitney Graybill2,
  3. Andrés Redondo3,
  4. David M O’malley4,
  5. Sileny Han5,
  6. Noelle Cloven6,
  7. Anja Ør Knudsen7,
  8. Stanislav Lechpammer8,
  9. Antonio González-Martín9 and
  10. Bradley J Monk10
  1. 1Sheba Medical Center, Sackler School of Medicine, Tel Aviv University; Gynecologic Oncology Department
  2. 2Gog; Medical University of South Carolina; Gynecologic Oncology
  3. 3Hospital Universitario La Paz, Idipaz
  4. 4Ohio State University, James Comprehensive Cancer Center
  5. 5University Hospitals Leuven; Department of Obstetrics and Gynecology
  6. 6Texas Oncology
  7. 7Odense University Hospital; Department of Oncology
  8. 8Glaxosmithkline
  9. 9Grupo Español de Investigación En Cáncer de Ovario (Geico); Clínica Universidad de Navarra; Medical Oncology Department
  10. 10Arizona Oncology (US Oncology Network); University of Arizona College of Medicine, Creighton University School of Medicine


Introduction/Background The PRIMA/ENGOT-OV26/GOG-3012 trial showed that niraparib significantly improves progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer (aOC) that responded to front-line platinum-based chemotherapy (hazard ratio, 0.62; 95% CI, 0.50–0.76). Based on these results, niraparib has been approved in the United States and the European Union for front-line maintenance treatment in patients with aOC. In this post hoc analysis, we report the efficacy of niraparib in patients with BRCA-mutated (BRCAm) aOC with an emphasis on efficacy and safety of fixed vs. individualized starting doses (FSD vs. ISD).

Methodology In this double-blind, placebo-controlled, randomised phase 3 trial, patients with newly diagnosed, high-grade aOC who responded to platinum-based chemotherapy were randomised 2:1 to receive FSD of niraparib 300 mg orally once daily (QD) or placebo. The trial was amended to incorporate an ISD of 200 mg orally QD for patients with a body weight <77 kg or platelet count <150,000/μL, and 300 mg QD in patients with a body weight ≥77 kg and platelet count ≥150,000/μL. Patients were stratified by best response to first-line chemotherapy (complete/partial response), receipt of neoadjuvant chemotherapy (yes/no), and homologous recombination status (deficient/proficient and not determined). BRCA status was determined in tumour samples at screening via the myChoice test (Myriad®). The post hoc BRCAm subgroup PFS analysis was performed using a stratified Cox proportional hazards model and Kaplan-Meier methodology. Safety and patient-reported outcome analyses were also performed.

Results The intention-to-treat population comprised 733 randomised patients, of which 223 (30%) had BRCAm tumours. Of those, 144 (65%) received FSD and 79 (35%) received ISD. Niraparib provided a comparable PFS benefit over placebo in patients receiving both FSD (hazard ratio, 0.44; 95% CI 0.26–0.73) and ISD (hazard ratio 0.29; 95% CI 0.13–0.67). A PFS subgroup analysis by patient characteristics is shown in table 1. A summary of grade ≥3 selected adverse events is shown in table 2.

Abstract 571 Table 1

PFS subgroup analysis analysis in patient with BRACAm

Abstract 571 Table 2

Summary of grade ≥3 adverse events in patients with BRCAm aOC

Conclusion Niraparib significantly improved PFS when utilised as maintenance treatment after front-line therapy in patients with BRCAm aOC. Patients receiving FSD or ISD derived similar PFS benefit, while the ISD group showed an improved safety profile.

Disclosures Dr. Graybill reports personal fees from GlaxoSmithKline.

Dr. Redondo reports institutional research funding from PharmaMar, Roche, and Eisai; and advisory roles at PharmaMar, AstraZeneca, Tesaro, Roche, and Eisai.

Dr. O’Malley reports personal fees from Immunogen, Eisai, Agenus, GlaxoSmithKline: Consultant/Advisory Board for Clovis, Ambry, Abbvie, Janssen/J&J, Regeneron, Novacure, Myraid Genetics, Tarveda, Amgen, VentiRx, Array Biopharma, EMD Serono, Ergomed; Steering committee for Genentech/Roche and Merck; Institutional funding from Ajinomoto Inc, Ludwig Cancer Research, Stemcentrx, Inc, CERULEAN PHARMA, GOG Foundation, BMS, Serono Inc, TRACON Pharmaceuticals, Yale University, New Mexico Cancer Care Alliance, INC Research, Inc., Inventiv Health Clinical, Iovance Biotherapeutics, Inc, and PRA International.

Dr. Gupta is an employee of GlaxoSmithKline.

Dr. González-Martín reports personal fees and non-financial support from AstraZeneca; grant and personal fees from GlaxoSmithKline, Clovis Oncology, Roche Holding AG, Merck & Co., Inc., Genmab, INMUNOGEN, Pharma Mar, S.A., and Oncoinvent AS.

Dr. Monk reports consulting and advisory role at Merck, GlaxoSmithKline, Roche/Genentech, AstraZeneca, Advaxiz, Cerulean Pharma, Amgen, Immunogen, NuCana BioMed, Clovis Oncology, Pfizer, Mateon Therapeutics, Precision Oncology, Perthera, Abbvie, Myriad Pharmaceuticals, Incyte, VBL Therapeutics, Takeda, Samumed, Oncomed, OncoSec, ChemoID, Geistlich Pharma, Eisai and Chemocare; Speakers’ bureau at Roche/Genentech, AstraZeneca, Janssen, Clovis Oncology and GlaxoSmithKline; Honoraria from Merck, GlaxoSmithKline, Roche/Genentech, AstraZeneca, Advaxis, Immunogen, NuCana BioMed, Clovis Oncology, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, ChemoID, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Genentech, Lilly, Janssen, Array BioPharma, GlaxoSmithKline, Morphotek, Pfizer, Advaxis, AstraZeneca, Immunogen, Regeneron, and Nucana.

Drs. Korach, Han, Cloven and Knudsen have nothing to disclose.

Funding GlaxoSmithKline (Waltham, MA)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.